CN104316696A - 用于检测jc多瘤病毒的方法 - Google Patents

用于检测jc多瘤病毒的方法 Download PDF

Info

Publication number
CN104316696A
CN104316696A CN201410478514.8A CN201410478514A CN104316696A CN 104316696 A CN104316696 A CN 104316696A CN 201410478514 A CN201410478514 A CN 201410478514A CN 104316696 A CN104316696 A CN 104316696A
Authority
CN
China
Prior art keywords
jcv
pml
experimenter
variant
virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201410478514.8A
Other languages
English (en)
Chinese (zh)
Inventor
利奥尼德·戈雷利克
阿列克谢·卢戈夫斯柯伊
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen Inc
Biogen MA Inc
Original Assignee
Biogen Idec MA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42542341&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN104316696(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biogen Idec MA Inc filed Critical Biogen Idec MA Inc
Publication of CN104316696A publication Critical patent/CN104316696A/zh
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/01—DNA viruses
    • G01N2333/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
CN201410478514.8A 2009-02-05 2010-02-05 用于检测jc多瘤病毒的方法 Pending CN104316696A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15031009P 2009-02-05 2009-02-05
US61/150,310 2009-02-05

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201080014394.6A Division CN102369436B (zh) 2009-02-05 2010-02-05 用于检测jc多瘤病毒的方法

Publications (1)

Publication Number Publication Date
CN104316696A true CN104316696A (zh) 2015-01-28

Family

ID=42542341

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201410478514.8A Pending CN104316696A (zh) 2009-02-05 2010-02-05 用于检测jc多瘤病毒的方法
CN201080014394.6A Active CN102369436B (zh) 2009-02-05 2010-02-05 用于检测jc多瘤病毒的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201080014394.6A Active CN102369436B (zh) 2009-02-05 2010-02-05 用于检测jc多瘤病毒的方法

Country Status (11)

Country Link
US (2) US20130101985A9 (cg-RX-API-DMAC7.html)
EP (1) EP2394163B1 (cg-RX-API-DMAC7.html)
JP (1) JP2012517017A (cg-RX-API-DMAC7.html)
CN (2) CN104316696A (cg-RX-API-DMAC7.html)
AU (1) AU2010210979B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI1016273A2 (cg-RX-API-DMAC7.html)
CA (1) CA2751364C (cg-RX-API-DMAC7.html)
ES (1) ES2842425T3 (cg-RX-API-DMAC7.html)
NZ (1) NZ594973A (cg-RX-API-DMAC7.html)
SG (2) SG173201A1 (cg-RX-API-DMAC7.html)
WO (1) WO2010090757A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112442553A (zh) * 2020-10-27 2021-03-05 深圳市罗湖区人民医院 一种用于JCPyV检测与分型的试剂盒及方法

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE047230T2 (hu) 2006-02-28 2020-04-28 Biogen Ma Inc Gyulladásos és autoimmun betegségek natalizumabbal való kezelésének módszerei
KR20080104343A (ko) 2006-03-03 2008-12-02 엘란 파마슈티칼스, 인크. 나탈리주마브로 염증 및 자가면역 질환을 치료하는 방법
AU2010210979B2 (en) 2009-02-05 2015-12-10 Biogen Ma Inc. Methods for the detection of JC polyoma virus
US11287423B2 (en) 2010-01-11 2022-03-29 Biogen Ma Inc. Assay for JC virus antibodies
BR112012017014B1 (pt) 2010-01-11 2021-07-20 Biogen Ma Inc Métodos para detecção de anticorpos de vírus jc
HUE061244T2 (hu) 2011-05-31 2023-06-28 Biogen Ma Inc A PML kockázat értékelésének módszere
HUE053664T2 (hu) 2011-07-18 2021-07-28 The United States Of America Eljárások és készítmények Polyomavírussal összefüggõ betegségek gátlására
EP2548567A1 (en) * 2011-07-22 2013-01-23 Universitätsklinikum Hamburg-Eppendorf Polyoma virus JC peptides and proteins in vaccination and diagnostic applications
EP2636746A1 (en) * 2012-03-06 2013-09-11 Life Science Inkubator A novel drug delivery system based on JCV-VLP
DK2828292T3 (da) 2012-03-20 2019-01-02 Biogen Ma Inc Jcv-neutraliserende antistoffer
EP3575311A1 (en) * 2012-03-20 2019-12-04 Biogen MA Inc. Jcv neutralizing antibodies
US9631243B2 (en) 2012-06-18 2017-04-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods and compositions for identifying JC virus
EP3517545A1 (en) 2012-12-31 2019-07-31 Neurimmune Holding AG Recombinant human antibodies for therapy and prevention of polyomavirus-related diseases
PL2774991T3 (pl) * 2013-03-06 2018-05-30 Life Science Inkubator Betriebs Gmbh & Co. Kg System dostarczania leków do stosowania w leczeniu lub diagnostyce zaburzeń neurologicznych
EP2971119A4 (en) * 2013-03-15 2016-11-02 Biogen Ma Inc MELT ANALYSIS ASSAY HIGHLY RESOLVED TO DETECT VIRAL DNA
EP3004334A4 (en) 2013-05-28 2016-12-21 Biogen Ma Inc METHOD FOR ASSESSING A PML RISK
US9931393B2 (en) 2013-12-20 2018-04-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Immunogenic JC polyomavirus compositions and methods of use
US20200197544A1 (en) * 2017-04-26 2020-06-25 Biogen Ma Inc. Jcv imaging methods and compositions

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3767755B2 (ja) * 1995-06-23 2006-04-19 エーザイ株式会社 抗jcウイルス抗体
DE19543553B4 (de) * 1995-11-22 2009-04-09 Deutsches Primatenzentrum Gmbh VP-Antigene des JC-Virus
BR9707207A (pt) 1996-01-26 1999-07-20 Univ California Filme polimérico ensaio e método para a detecção colorimétrica direta de analisados
DE10131145B4 (de) * 2001-06-28 2005-07-14 Innovent E.V. Zusammensetzung zum zellspezifischen Transfer von Wirkstoffen
JP4840792B2 (ja) 2001-11-22 2011-12-21 独立行政法人科学技術振興機構 JCウイルスagnoを対象としたPMLの治療
US20080131928A1 (en) 2004-07-01 2008-06-05 Hiroshi Handa Viral Particle-Like Construct and Method of Forming the Same Under Physiological Conditions
JP4757103B2 (ja) 2005-06-13 2011-08-24 学校法人関西文理総合学園 試料中のウイルスを検出する方法およびシステム
US7468186B2 (en) 2005-07-22 2008-12-23 City Of Hope Polyomavirus cellular epitopes and uses therefor
EP1951888B1 (en) 2005-11-09 2012-09-05 PrimeraDx, Inc. Multiplexed quantitative detection of pathogens
US7769230B2 (en) * 2006-11-30 2010-08-03 Eastman Kodak Company Producing low resolution images
WO2008077511A1 (en) 2006-12-22 2008-07-03 Karolinska Institutet Innovations Ab Human polyomavirus and methods of diagnosis and treatment
JP2008249433A (ja) 2007-03-29 2008-10-16 Kansai Bunri Sogo Gakuen 被験物質に対するプローブの結合親和性を測定する方法及びその利用
US20110118340A1 (en) 2008-02-08 2011-05-19 Muthiah Manoharan Delivery of rnai constructs to oligodendrocytes
AU2010210979B2 (en) 2009-02-05 2015-12-10 Biogen Ma Inc. Methods for the detection of JC polyoma virus
MX2014001224A (es) 2011-07-29 2015-03-09 Biogen Idec Inc Ensayo para la detección de adn del virus jc.
AR095089A1 (es) 2013-01-30 2015-09-30 Biogen Idec Inc Ensayo de detección de adn de virus jc

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112442553A (zh) * 2020-10-27 2021-03-05 深圳市罗湖区人民医院 一种用于JCPyV检测与分型的试剂盒及方法

Also Published As

Publication number Publication date
US9696307B2 (en) 2017-07-04
SG173201A1 (en) 2011-08-29
JP2012517017A (ja) 2012-07-26
CN102369436A (zh) 2012-03-07
CN102369436B (zh) 2014-10-22
EP2394163A1 (en) 2011-12-14
EP2394163B1 (en) 2020-08-19
NZ594973A (en) 2012-05-25
CA2751364A1 (en) 2010-08-12
US20130101985A9 (en) 2013-04-25
EP2394163A4 (en) 2012-08-01
US20150219651A1 (en) 2015-08-06
BRPI1016273A2 (pt) 2020-12-01
WO2010090757A1 (en) 2010-08-12
CA2751364C (en) 2017-06-20
SG2014009120A (en) 2014-03-28
AU2010210979B2 (en) 2015-12-10
ES2842425T3 (es) 2021-07-14
AU2010210979A1 (en) 2011-09-22
US20120258443A1 (en) 2012-10-11

Similar Documents

Publication Publication Date Title
CN102369436B (zh) 用于检测jc多瘤病毒的方法
Tortorici et al. Broad sarbecovirus neutralization by a human monoclonal antibody
Wang et al. Memory B cell repertoire from triple vaccinees against diverse SARS-CoV-2 variants
Pinto et al. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody
Walls et al. Unexpected receptor functional mimicry elucidates activation of coronavirus fusion
Javanmardi et al. Antibody escape and cryptic cross-domain stabilization in the SARS-CoV-2 Omicron spike protein
Liu et al. Inactivated vaccine-elicited potent antibodies can broadly neutralize SARS-CoV-2 circulating variants
Shang et al. NRP1 is a receptor for mammalian orthoreovirus engaged by distinct capsid subunits
Li et al. Structural basis of a two-antibody cocktail exhibiting highly potent and broadly neutralizing activities against SARS-CoV-2 variants including diverse Omicron sublineages
Zhang et al. Discovery and characterization of potent broadly neutralizing antibodies from human survivors of severe fever with thrombocytopenia syndrome
Ssebyatika et al. Broadly neutralizing antibodies isolated from HEV convalescents confer protective effects in human liver-chimeric mice
Callegari et al. Potent neutralization by monoclonal human IgM against SARS‐CoV‐2 is impaired by class switch
Geng et al. Lys417 acts as a molecular switch that regulates the conformation of SARS-CoV-2 spike protein
Wang et al. Longitudinal and proteome-wide analyses of antibodies in COVID-19 patients reveal features of the humoral immune response to SARS-CoV-2
Su et al. A human monoclonal antibody neutralizes SARS-CoV-2 Omicron variants by targeting the upstream region of spike protein HR2 motif
TWI617573B (zh) 用於酵素置換療法的改造酵素
CN117866083A (zh) 一种抗新型冠状病毒的全人源单克隆抗体及其用途
Wang et al. A subset of Memory B-derived antibody repertoire from 3-dose vaccinees is ultrapotent against diverse and highly transmissible SARS-CoV-2 variants, including Omicron
US20150233924A1 (en) Methods for identifying hiv neutralizing antibodies
US7977098B2 (en) Antigenic binding patterns of norovirus to human histo-blood group antigens
Asano et al. Identification of antigenic peptides derived from B-cell epitopes of nucleocapsid protein of mouse hepatitis virus for serological diagnosis
Matveev et al. Novel B-Cell Epitopes of Non-Neutralizing Antibodies in the Receptor-Binding Domain of the SARS-CoV-2 S-Protein with Different Effects on the Severity of COVID-19
Fenwick et al. ACE2 mimetic antibody potently neutralizes all SARS-CoV-2 variants and fully protects in XBB. 1.5 challenged monkeys
Costanzo Structural and functional characterization of a humanized neutralizing antibody targeting the SARS-CoV-2 Receptor Binding Domain (RBD)
CN116829177A (zh) 抗SARS-CoV-2的有效中和抗体及其生成和用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C53 Correction of patent for invention or patent application
CB02 Change of applicant information

Address after: Massachusetts, USA

Applicant after: Biological gene MA company

Address before: Massachusetts, USA

Applicant before: Bio gene IDEC MA

COR Change of bibliographic data

Free format text: CORRECT: ADDRESS; FROM:

Free format text: CORRECT: APPLICANT; FROM: BIOGEN IDEC MA LTD. TO: BIOGEN MA INC.

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20150128